

Onconova Therapeutics, Inc.
 Form 3
 July 24, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â GROOPMAN JEROME
 (Last) (First) (Middle)

C/O ONCONOVA THERAPEUTICS, INC.,Â 375 PHEASANT RUN
 (Street)

NEWTOWN,Â PAÂ 18940
 (City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
 07/24/2013

3. Issuer Name and Ticker or Trading Symbol
 Onconova Therapeutics, Inc. [ONTX]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer Other
 (give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

Edgar Filing: Onconova Therapeutics, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (right to purchase)	03/09/2006	03/10/2015	Common Stock	375	\$ 1.33	D	Â
Stock Option (right to purchase)	04/26/2006	04/27/2015	Common Stock	375	\$ 1.33	D	Â
Stock Option (right to purchase)	10/06/2006	10/07/2015	Common Stock	750	\$ 2.67	D	Â
Stock Option (right to purchase)	10/19/2006	10/20/2015	Common Stock	1,500	\$ 2.67	D	Â
Stock Option (right to purchase)	01/11/2007	01/12/2016	Common Stock	1,500	\$ 2.67	D	Â
Stock Option (right to purchase)	10/06/2006	10/06/2016	Common Stock	375	\$ 2.67	D	Â
Stock Option (right to purchase)	01/11/2008	01/11/2017	Common Stock	1,500	\$ 6	D	Â
Stock Option (right to purchase)	01/11/2007	01/11/2017	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	02/26/2007	02/26/2017	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	03/06/2007	03/06/2017	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	03/29/2007	03/29/2017	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	05/08/2007	05/08/2017	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	12/31/2008	01/01/2018	Common Stock	2,250	\$ 6	D	Â
Stock Option (right to purchase)	01/16/2008	01/16/2018	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	02/12/2008	02/12/2018	Common Stock	187	\$ 6	D	Â
Stock Option (right to purchase)	05/31/2008	06/01/2018	Common Stock	375	\$ 6	D	Â
Stock Option (right to purchase)	12/31/2012	01/01/2022	Common Stock	2,625	\$ 6.13	D	Â
Stock Option (right to purchase)	06/06/2011	06/06/2021	Common Stock	375	\$ 6.13	D	Â
Stock Option (right to purchase)	01/01/2012	01/01/2021	Common Stock	2,250	\$ 6.13	D	Â

Edgar Filing: Onconova Therapeutics, Inc. - Form 3

Stock Option (right to purchase)	09/30/2010	09/30/2020	Common Stock	375	\$ 6.13	D	Â
Stock Option (right to purchase)	01/01/2011	01/02/2020	Common Stock	2,250	\$ 5.76	D	Â
Stock Option (right to purchase)	11/30/2009	12/01/2019	Common Stock	375	\$ 5.76	D	Â
Stock Option (right to purchase)	09/29/2009	09/30/2019	Common Stock	375	\$ 5.76	D	Â
Stock Option (right to purchase)	07/23/2009	07/24/2019	Common Stock	375	\$ 5.76	D	Â
Stock Option (right to purchase)	03/24/2009	03/25/2019	Common Stock	375	\$ 5.76	D	Â
Stock Option (right to purchase)	02/20/2009	02/21/2019	Common Stock	187	\$ 5.76	D	Â
Stock Option (right to purchase)	01/01/2010	01/02/2019	Common Stock	2,250	\$ 5.76	D	Â
Stock Option (right to purchase)	09/10/2008	09/11/2018	Common Stock	187	\$ 6	D	Â
Stock Option (right to purchase)	07/22/2008	07/23/2018	Common Stock	187	\$ 6	D	Â
Stock Option (right to purchase)	05/31/2008	06/01/2018	Common Stock	375	\$ 6	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GROOPMAN JEROME C/O ONCONOVA THERAPEUTICS, INC. 375 PHEASANT RUN NEWTOWN, PA 18940	Â X	Â	Â	Â

Signatures

/s/ Ajay Bansal, as attorney
in fact

07/24/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Â

Remarks:

One of Two.

Edgar Filing: Onconova Therapeutics, Inc. - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.